NSCLC Patients See Significant Survival Benefit from Tecentriq, Study Finds
News
Patients with advanced or metastatic non-small cell lung cancer (NSCLC) whose disease progressed on platinum-based chemotherapy benefit more from the anti-PD-L1 immunotherapy Tecentriq (atezolizumab) than from standard Taxotere (docetaxel) chemotherapy, results of a ... Read more